American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Well-Being and Resilience

Resources addressing burnout among clinicians and trainees

Professional Development

Services to support hematologists with continuing medical education and recertification

Clinical Priorities

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors

    The Food and Drug Administration approved emicizumab-kxwh injection (HEMLIBRA, Genentech, Inc.) for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.

  • FDA Grants Regular Approval to Duvelisib

    The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.

  • FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukemia

    The Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITI, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

  • FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome

    The Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo, Kyowa Kirin, Inc.) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

View all FDA alerts
  • CMS Releases National Coverage Determination on Next Generation Sequencing

    CMS released a National Coverage Determination entitled Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer. ASH submitted comments on the proposal along with over 300 other groups, including physician specialty societies, patient advocacy groups, and industry groups.

  • ASH Applauds the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018

    Senators Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018.

  • Update on Tax Reform

    On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.

  • 2017 Action of the Affordable Care Act

    Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.

View all policy news
back to top